Literature DB >> 22228569

Subcutaneous immunoglobulin replacement therapy with Hizentra® is safe and effective in two infants.

Joel L Gallagher1, Niraj C Patel.   

Abstract

Hizentra® is a 20% liquid IgG product approved for subcutaneous administration in adults and children greater than 2 years of age. We report two infants less than 2 years in which administration of Hizentra® was safe and effective.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22228569     DOI： 10.1007/s10875-011-9645-0

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN： 0271-9142            Impact factor:   8.317


  10 in total

1.  NETHERTON'S DISEASE; TRICHORRHEXIS INVAGINATA (BAMBOO HAIR), CONGENITAL ICHTHYOSIFORM ERYTHRODERMA AND THE ATOPIC DIATHESIS. A HISTOPATHOLOGIC STUDY.

Authors:  R D WILKINSON; G H CURTIS; W A HAWK
Journal:  Arch Dermatol       Date:  1964-01

2.  Rapid subcutaneous IgG replacement therapy is effective and safe in children and adults with primary immunodeficiencies--a prospective, multi-national study.

Authors:  Ann Gardulf; Uwe Nicolay; Oscar Asensio; Ewa Bernatowska; Andreas Böck; Beatriz Costa Carvalho; Carl Granert; Stefan Haag; Dolores Hernández; Peter Kiessling; Jan Kus; Jaune Pons; Tim Niehues; Sigune Schmidt; Ilka Schulze; Michael Borte
Journal:  J Clin Immunol       Date:  2006-04-26       Impact factor: 8.317

3.  [Not Available].

Authors:  M COMEL
Journal:  Dermatologica       Date:  1949

Review 4.  Subcutaneous administration of IgG.

Authors:  Melvin Berger
Journal:  Immunol Allergy Clin North Am       Date:  2008-11       Impact factor: 3.479

5.  Efficacy and safety of Hizentra(®) in patients with primary immunodeficiency after a dose-equivalent switch from intravenous or subcutaneous replacement therapy.

Authors:  S Jolles; E Bernatowska; J de Gracia; M Borte; V Cristea; H H Peter; B H Belohradsky; V Wahn; J Neufang-Hüber; O Zenker; B Grimbacher
Journal:  Clin Immunol       Date:  2011-06-12       Impact factor: 3.969

6.  Children and adults with primary antibody deficiencies gain quality of life by subcutaneous IgG self-infusions at home.

Authors:  Ann Gardulf; Uwe Nicolay; Dipl Math; Oscar Asensio; Ewa Bernatowska; Andreas Böck; Beatriz T Costa-Carvalho; Carl Granert; Stefan Haag; Dolores Hernández; Peter Kiessling; Jan Kus; Nuria Matamoros; Tim Niehues; Sigune Schmidt; Ilka Schulze; Michael Borte
Journal:  J Allergy Clin Immunol       Date:  2004-10       Impact factor: 10.793

Review 7.  Netherton's syndrome: a syndrome of elevated IgE and characteristic skin and hair findings.

Authors:  D L Smith; J G Smith; S W Wong; R D deShazo
Journal:  J Allergy Clin Immunol       Date:  1995-01       Impact factor: 10.793

8.  Comèl-Netherton syndrome defined as primary immunodeficiency.

Authors:  Ellen D Renner; Dominik Hartl; Stacey Rylaarsdam; Marguerite L Young; Linda Monaco-Shawver; Gary Kleiner; M Louise Markert; E Richard Stiehm; Bernd H Belohradsky; Melissa P Upton; Troy R Torgerson; Jordan S Orange; Hans D Ochs
Journal:  J Allergy Clin Immunol       Date:  2009-08-14       Impact factor: 10.793

9.  Efficacy and safety of hizentra®, a new 20% immunoglobulin preparation for subcutaneous administration, in pediatric patients with primary immunodeficiency.

Authors:  Michael Borte; Malgorzata Pac; Margit Serban; Teresa Gonzalez-Quevedo; Bodo Grimbacher; Stephen Jolles; Othmar Zenker; Jutta Neufang-Hueber; Bernd Belohradsky
Journal:  J Clin Immunol       Date:  2011-06-15       Impact factor: 8.317

10.  Safety and efficacy of self-administered subcutaneous immunoglobulin in patients with primary immunodeficiency diseases.

Authors:  Hans D Ochs; Sudhir Gupta; Peter Kiessling; Uwe Nicolay; Melvin Berger
Journal:  J Clin Immunol       Date:  2006-05       Impact factor: 8.542
  10 in total
  3 in total

Review 1.  Netherton Syndrome: A Genotype-Phenotype Review.

Authors:  Constantina A Sarri; Angeliki Roussaki-Schulze; Yiannis Vasilopoulos; Efterpi Zafiriou; Aikaterini Patsatsi; Costas Stamatis; Polyxeni Gidarokosta; Dimitrios Sotiriadis; Theologia Sarafidou; Zissis Mamuris
Journal:  Mol Diagn Ther       Date:  2017-04       Impact factor: 4.074

2.  Outcomes of Systemic Treatment in Children and Adults With Netherton Syndrome: A Systematic Review.

Authors:  Anouk E M Nouwen; Renske Schappin; N Tan Nguyen; Aviël Ragamin; Anette Bygum; Christine Bodemer; Virgil A S H Dalm; Suzanne G M A Pasmans
Journal:  Front Immunol       Date:  2022-03-30       Impact factor: 8.786

3.  Subcutaneous Immunoglobulin Replacement Therapy with Hizentra® is Safe and Effective in Children Less Than 5 Years of Age.

Authors:  Niraj C Patel; Joel L Gallagher; Hans D Ochs; Thomas Prescott Atkinson; Justin Wahlstrom; Morna Dorsey; Francisco A Bonilla; Jennifer Heimall; Lisa Kobrynski; David Morris; Elie Haddad
Journal:  J Clin Immunol       Date:  2015-09-04       Impact factor: 8.317
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.